Partnership Models

GARDP will work largely as a virtual R&D initiative through direct partnerships and multi-stakeholder collaborations, including with academia, industry, international organizations and governments. Working with patented and non-patented drug candidates, GARDP will follow DNDi’s access-driven intellectual property policy in its agreements. While maintaining a clear focus and strategy for all its programmatic interventions,

GARDP will develop partnership models tailored to the capacity and ability of actors involved: in certain programmes, GARDP will need to be actively driving and implementing R&D programmes, while in others, equitable partnerships will be sought whereby GARDP brings in the appropriate amount of funding, direction, and support. All GARDP funding will be linked to the need to develop and make available affordable products that answer to public health needs.

A global collaboration

Partnerships with Governments, academia, research centres and industry are at the heart of GARDP’s work. Without their support, GARDP would not have been able to make the progress it has made so far.

Belgium

• University of Antwerp

Denmark

• REPAIR Impact Fund

EU

Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)

India

• All India Institute of Medical Sciences (AIIMS)
• Indian Council of Medical Research

Italy

• Penta Foundation

Japan

• Eisai
• Takeda

 

Kenya

• Kenyan Medical Research Institute (KEMRI)

Korea

• Institut Pasteur Korea

The Netherlands

• Department of Infectious Diseases,
Public Health Service Amsterdam

South Africa

• National Institute for Communicable Diseases (NICD)
• South African Medical Research Council (SAMRC)
• Stellenbosch University
• University of KwaZulu Natal
• Wits Health Consortium (WHC)
• Wits Reproductive Health and HIV (Wits RHI), University of Witwatersrand 

Sweden

• WHO Collaborating Centre for Gonorrhoea and other sexually transmitted infections,
University Hospital, Örebro (WHOCC)

Switzerland

• European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

• Foundation for Innovative New Diagnostics (FIND)

• Sandoz, the Novartis generics division

Thailand

• Bureau of AIDS, TB, and STIs
• Department of Disease Control
• Ministry of Public Health
• Thailand US CDC Collaboration
• Thai Red Cross, AIDS Research Center
• University of Mahidol, Tropical Medicine Hospital

United Kingdom

• British Society of Antimicrobial Chemotherapy (BSAC)
• St George’s, University of London
• Medical Research Council – Clinical Trials Unit (MRC CTU) at University
College – London (UCL)
• The University of Liverpool
• The Wellcome Trust

United States

• American Society of Microbiology (ASM)
• CARB-X, Combating Antibiotic Resistant Bacteria, led by Boston University 
• Entasis Therapeutics
• National Institutes of Health (NIH)
• National Institute of Allergy and Infectious Diseases (NIAID)
• The Pew Charitable Trusts
• University of Alabama
• University of Florida

GARDP is collaborating with research centres on specific studies in the following countries:

Bangladesh, Brazil, China, Greece, India, Italy, Kenya, The Netherlands, South Africa, Thailand, Vietnam, and Uganda, United States.